BioVie Announces Closing of Public Offering of Common Stock
23. September 2020 08:00 ET
|
BioVie Inc.
SANTA MONICA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today...
Highly Accomplished Executives Join BioVie’s Board of Directors
16. Juni 2020 08:30 ET
|
BioVie Inc.
Hariri, Gorlin, and Rogich to Contribute Their Tremendous Industry Insights and Stature SANTA MONICA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- BioVie, Inc. (OTCQB: BIVI) (“BioVie” or...
BioVie Advances the BIV201 Clinical Program and Prefilled Syringe
11. Juni 2020 08:30 ET
|
BioVie Inc.
Novel BIV201 Formulation Shows Significant Improvements Over Industry TerlipressinPrefilled Syringe May Significantly Extend Market Protection Beyond Orphan Drug Exclusivity SANTA MONICA, Calif.,...
BioVie Manufactures Novel Terlipressin Prefilled Syringe
09. Dezember 2019 08:00 ET
|
BioVie Inc.
SANTA MONICA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVID) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced...
BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites
30. April 2019 08:00 ET
|
BioVie Inc.
LOS ANGELES, April 30, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced...
BioVie to Present at ThinkEquity Conference in NYC on May 2nd
24. April 2019 07:00 ET
|
BioVie Inc.
LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr....
BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
06. Februar 2019 08:00 ET
|
BioVie Inc.
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today...
BioVie Inc. (OTCQB:BIVI) Attains Milestone
09. April 2018 07:00 ET
|
BioVie Inc.
BEVERLY, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease,...
BioVie to Present at The MicroCap Conference in New York on April 9th
22. März 2018 07:00 ET
|
BioVie Inc.
BEVERLY, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease,...
BioVie Responds to Japan Patent Office and Comments on Recent Stock Price Decline
07. März 2018 07:00 ET
|
BioVie Inc.
BEVERLY, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease,...